Zhitong Finance App News, Federal Pharmaceuticals (03933.HK) announced that UBT251 injection, a Class 1 innovative drug independently developed by the company's wholly-owned subsidiary Federal Biotechnology (Zhuhai Hengqin) Co., Ltd. (Federal Biotechnology), has completed administration to participants in the first phase III clinical study of overweight/obesity in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.